Edwards Lifesciences stock surged Wednesday — and retook both its key moving averages — after beating fourth-quarter forecasts for its heart-valve replacements. Please watch the video at ...

Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical ...

Capstan Medical, a startup focused on robotic-assisted mitral and tricuspid valve replacement, recently completed its first ...

Edwards Lifesciences Corp. engages in the patient ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter ...

Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices.

Edwards Lifesciences stock popped Wednesday on strong ... Transcatheter Aortic Valve Replacement (TAVR) global sales grew 5.3% year-over-year to $1.04 billion in the fourth quarter.

Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...

Edwards Lifesciences finished 2024 with solid fourth ... Edwards reached an inflection point in 2024 with transcatheter aortic valve, or TAVR, sales slowing, while the launch of and revenue ...

We recently published an article titled Top 12 Stocks to Buy According to Citadel Investment Group. In this article, we are ...

July 15, 2024--Edwards Lifesciences (NYSE: EW) today announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR ...